<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00047333</url>
  </required_header>
  <id_info>
    <org_study_id>NCI-2012-02498</org_study_id>
    <secondary_id>ID02-008</secondary_id>
    <secondary_id>CDR0000257665</secondary_id>
    <nct_id>NCT00047333</nct_id>
  </id_info>
  <brief_title>Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed</brief_title>
  <official_title>A Phase 2 Open-Label Study Of OSI-774 (NSC 718781) In Unresectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      Phase II trial to study the effectiveness of erlotinib in treating patients who have liver&#xD;
      cancer that cannot be surgically removed. Erlotinib may stop the growth of tumor cells by&#xD;
      blocking the enzymes necessary for their growth&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      PRIMARY OBJECTIVES:&#xD;
&#xD;
      I. To assess progression-free survival (PFS) measured at 16 weeks following initiation of&#xD;
      once daily continuous oral therapy with OSI-774 in patients with unresectable hepatocellular&#xD;
      carcinoma.&#xD;
&#xD;
      SECONDARY OBJECTIVES:&#xD;
&#xD;
      I. To assess objective response rate, rate and duration of stable disease, time to&#xD;
      progression, median and overall survival in this patient population, and any changes in tumor&#xD;
      perfusion based on functional CT imaging.&#xD;
&#xD;
      II. To correlate response with patient characteristics including: age, disease stage (TNM,&#xD;
      Okuda [6]), viral hepatitis status, pathologic grade of cirrhosis, Childs-Pugh status,&#xD;
      Performance Status, serum values of: alpha feto-protein, bilirubin, transaminases, albumin;&#xD;
      EGFR expression score by IHC; and development of skin rash during therapy.&#xD;
&#xD;
      III. To determine the pharmacokinetic and pharmacodynamic profile of OSI-774 in this patient&#xD;
      population.&#xD;
&#xD;
      IV. To determine the safety and tolerability of OSI-774 in this patient population.&#xD;
&#xD;
      OUTLINE: Patients are stratified according to epidermal growth factor receptor expression&#xD;
      (low, 0-1+ vs high, 2-3+).&#xD;
&#xD;
      Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of&#xD;
      disease progression or unacceptable toxicity.&#xD;
&#xD;
      Patients are followed every 3 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Administratively complete.&#xD;
  </why_stopped>
  <start_date>August 2002</start_date>
  <primary_completion_date type="Actual">January 2006</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>Time from initiation of therapy until documented disease progression, assessed at 16 weeks</time_frame>
    <description>Summarized by Kaplan-Meier curves, from which medians and progression-free survival can be attained.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective response rate</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summarized by estimates and standard errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of stable disease</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summarized by estimates and standard errors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of stable disease</measure>
    <time_frame>From the start of the treatment until the criteria for progression are met, assessed up to 4 years</time_frame>
    <description>Summarized by Kaplan-Meier curves, from which medians and overall duration of stable disease can be attained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to progression</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summarized by Kaplan-Meier curves, from which medians and time to progression can be attained.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>Up to 4 years</time_frame>
    <description>Summarized by Kaplan-Meier curves, from which medians and overall survival can be attained.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">80</enrollment>
  <condition>Adult Primary Hepatocellular Carcinoma</condition>
  <condition>Advanced Adult Primary Liver Cancer</condition>
  <condition>Localized Unresectable Adult Primary Liver Cancer</condition>
  <arm_group>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive oral erlotinib once daily. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>erlotinib hydrochloride</intervention_name>
    <description>Given PO</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>CP-358,774</other_name>
    <other_name>erlotinib</other_name>
    <other_name>OSI-774</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>laboratory biomarker analysis</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>pharmacological study</intervention_name>
    <description>Correlative studies</description>
    <arm_group_label>Treatment (erlotinib hydrochloride)</arm_group_label>
    <other_name>pharmacological studies</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed hepatocellular carcinoma (HCC)not amenable to curative&#xD;
             resection&#xD;
&#xD;
               -  No fibrolamellar HCC&#xD;
&#xD;
          -  No prior therapy for HCC, including systemic chemotherapy, hepatic arterial infusion&#xD;
             of chemotherapeutic agents or irradiated microspheres, and epidermal growth factor&#xD;
             receptor-targeting agents&#xD;
&#xD;
               -  The following prior therapies are allowed provided previously treated lesions&#xD;
                  remain separate from those to be evaluated in present study&#xD;
&#xD;
                    -  Surgery&#xD;
&#xD;
                    -  Liver-directed therapy (e.g., radiofrequency ablation, transarterial&#xD;
                       embolization/chemoembolization, or percutaneous ethanol injection)&#xD;
&#xD;
          -  At least 1 unidimensionally measurable lesion&#xD;
&#xD;
               -  At least 20 mm by conventional techniques&#xD;
&#xD;
          -  Must have paraffin tissue block or unstained slides from biopsy or surgical specimen&#xD;
&#xD;
          -  No known brain metastases&#xD;
&#xD;
          -  No ascites that are refractory to conservative management (e.g., sodium restriction to&#xD;
             50 mEq/day dietary sodium and fluid restrictions and/or diuretics)&#xD;
&#xD;
          -  Performance status - ECOG 0-2&#xD;
&#xD;
          -  At least 16 weeks&#xD;
&#xD;
          -  Granulocyte count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 60,000/mm^3&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Bilirubin no greater than 1.8 mg/dL&#xD;
&#xD;
          -  Albumin at least 2.5 g/dL&#xD;
&#xD;
          -  AST/ALT no greater than 5 times upper limit of normal&#xD;
&#xD;
          -  PT no greater than 1-3 seconds over normal&#xD;
&#xD;
          -  No decompensated liver disease&#xD;
&#xD;
          -  No jaundice&#xD;
&#xD;
          -  No portosystemic encephalopathy (evidenced by confusion, asterixis, significant sleep&#xD;
             disturbance, or hypothermia less than 36º Celsius)&#xD;
&#xD;
          -  No hyponatremia with sodium less than 125 mEq/L&#xD;
&#xD;
          -  No portal hypertension with bleeding esophageal or gastric varices within the past 3&#xD;
             months&#xD;
&#xD;
          -  Creatinine no greater than 2 mg/dL&#xD;
&#xD;
          -  No symptomatic congestive heart failure&#xD;
&#xD;
          -  No unstable angina pectoris&#xD;
&#xD;
          -  No cardiac arrhythmia&#xD;
&#xD;
          -  No gastrointestinal tract disease resulting in an inability to take oral medication or&#xD;
             requirement for IV alimentation&#xD;
&#xD;
          -  No active peptic ulcer disease&#xD;
&#xD;
          -  No abnormalities of the cornea (e.g., dry eye syndrome or Sjögren's syndrome)&#xD;
&#xD;
          -  No congenital abnormality (e.g., Fuch's dystrophy)&#xD;
&#xD;
          -  No other uncontrolled concurrent illness that would preclude study participation&#xD;
&#xD;
          -  No ongoing or active infection&#xD;
&#xD;
          -  No psychiatric illness or social situation that would preclude study compliance&#xD;
&#xD;
          -  No other malignancy within the past 5 years except nonmelanoma skin cancer&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No prior surgical therapy affecting absorption&#xD;
&#xD;
          -  More than 30 days since prior investigational agents&#xD;
&#xD;
          -  No concurrent commercial or other investigational anticancer agents or therapies&#xD;
&#xD;
          -  No concurrent combination antiretroviral therapy for HIV-positive patients&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Melanie Thomas</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>M D Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <study_first_submitted>October 3, 2002</study_first_submitted>
  <study_first_submitted_qc>January 26, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 27, 2003</study_first_posted>
  <last_update_submitted>January 22, 2013</last_update_submitted>
  <last_update_submitted_qc>January 22, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

